7 active not recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 7 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) Tibulizumab, Placebo - Systemic Sclerosis (SSc), Scleroderma | Phase 2 | Active not recruiting | Zura Bio Inc | 80 | 2025-02-06 | 2026-07-20 |
| A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis Efgartigimod PH20 SC, Placebo PH20 SC - Systemic Sclerosis (SSc) | Phase 2 | Active not recruiting | argenx | 87 | 2024-11-11 | 2026-10-16 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis rapcabtagene autoleucel, rituximab - Scleroderma, Diffuse | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 96 | 2024-10-29 | 2026-09-02 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis Placebo, Ianalumab - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 201 | 2024-10-09 | 2026-10-13 |
| Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Tulisokibart, Companion diagnostic ( CDx), Placebo - Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease | Phase 2 | Active not recruiting | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 154 | 2022-03-29 | 2026-09-22 |
| Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis Belimumab, Rituximab, Placebo Subcutaneous Injection - Systemic Sclerosis | Phase 2 | Active not recruiting | Hospital for Special Surgery, New York | 30 | 2019-07-29 | 2026-10-14 |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Oral Ifetroban, Oral Placebo - Scleroderma, Diffuse, Scleroderma, Systemic | Phase 2 | Active not recruiting | Cumberland Pharmaceuticals | 34 | 2017-01-01 | 2026-09-02 |
Scleroderma, Diffuse (5) · Autoimmune Diseases (2) · Lung Diseases, Interstitial (2) · Skin Diseases (2) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Pathologic Processes (1) · Scleroderma, Limited (1)
Skin and Connective Tissue Diseases (7) · Connective Tissue Diseases (6) · Skin Diseases (5) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Immune System Diseases (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (2) · Mycophenolic Acid (1) · belimumab (1) · ianalumab (1) · ifetroban (1)
Novartis Pharmaceuticals (2) · Cumberland Pharmaceuticals (1) · Hospital for Special Surgery, New York (1) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Zura Bio Inc (1) · argenx (1)
United States (7) · Argentina (5) · Hungary (5) · Mexico (5) · Spain (5) · United Kingdom (5) · Belgium (4) · France (4) · Germany (4) · Italy (4) · Poland (4) · Chile (3) · Netherlands (3) · Switzerland (3) · Australia (2)
Evan Brittain, MD (1) · Prometheus Biosciences (1) · Robert Spiera, MD (1)
2023 (2)